Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...
No additional exclusions were applied by the investigators during screening. The patients were randomised (1:1:1) to receive either ranibizumab 0.5 mg T&E with laser (T&E+laser; n=121), ranibizumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback